Literature DB >> 16503553

The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma.

Se-Hoon Lee, Yong Chan Ahn, Won Seog Kim, Young H Ko, Kihyun Kim, Keunchil Park.   

Abstract

We treated 17 patients with localized, nasal NK/T-cell lymphoma with two cycles of dose-intense CHOP (DI-CHOP) and early involved field radiation (IFRT). Sixteen out of 17 patients were evaluable for response. After two cycles of DICHOP, nine patients achieved complete remission (CR) (53%) and six had partial remissions (35%). After IFRT, 13 patients achieved CR (CR rate 76%; 95% CI, 56%-96%). The 3-year progression-free and overall survival rates were 56%, and 67%, respectively. This study shows that anthracycline-based chemotherapy seems to be ineffective in decreasing systemic failure even when administered at maximal dose intensity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16503553

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  12 in total

Review 1.  Treatment of localized extranodal NK/T cell lymphoma, nasal type.

Authors:  Seok Jin Kim; Won Seog Kim
Journal:  Int J Hematol       Date:  2010-11-18       Impact factor: 2.490

Review 2.  Current and future management of NK/T-cell lymphoma based on clinical trials.

Authors:  Motoko Yamaguchi
Journal:  Int J Hematol       Date:  2012-10-17       Impact factor: 2.490

3.  Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.

Authors:  J Lee; C Suh; H J Kang; B-Y Ryoo; J Huh; Y H Ko; H-S Eom; K Kim; K Park; W S Kim
Journal:  Ann Oncol       Date:  2008-08-09       Impact factor: 32.976

4.  Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma.

Authors:  Hee Kyung Ahn; Seok Jin Kim; Deok Won Hwang; Young Hyeh Ko; Tiffany Tang; Soon Thye Lim; Won Seog Kim
Journal:  Invest New Drugs       Date:  2012-10-28       Impact factor: 3.850

5.  A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma.

Authors:  Abeer N Abouyabis; Pareen J Shenoy; Rajni Sinha; Christopher R Flowers; Mary Jo Lechowicz
Journal:  ISRN Hematol       Date:  2011-06-16

Review 6.  Prognostic significance of Epstein-Barr virus DNA in NK/T-cell lymphoma: a meta-analysis.

Authors:  Qian Fei; Xiao-Kang Tian; Jing Wu; Hong-Ming Zhu; Yan Wang; Fan-Yu Peng; Wen-Jun Zhang; Li Yin; Xia He
Journal:  Onco Targets Ther       Date:  2018-02-26       Impact factor: 4.147

Review 7.  Extranodal NK/T cell lymphoma.

Authors:  Seong Hyun Jeong
Journal:  Blood Res       Date:  2020-07-31

8.  Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma.

Authors:  Shao-Qing Niu; Yong Yang; Yi-Yang Li; Ge Wen; Liang Wang; Zhi-Ming Li; Han-Yu Wang; Lu-Lu Zhang; Yun-Fei Xia; Yu-Jing Zhang
Journal:  Chin J Cancer       Date:  2016-04-04

9.  The Roles of Radiotherapy and Chemotherapy in the Era of Multimodal Treatment for Early-Stage Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma.

Authors:  Tae Hyung Kim; Jin Seok Kim; Yang Gun Suh; Jaeho Cho; Woo Ick Yang; Chang Ok Suh
Journal:  Yonsei Med J       Date:  2016-07       Impact factor: 2.759

10.  Five-year analysis from phase 2 trial of "sandwich" chemoradiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.

Authors:  Li Zhang; Ming Jiang; Li Xie; Hong Zhang; Yu Jiang; Qun-pei Yang; Wei-ping Liu; Wen-yan Zhang; Hong-yu Zhuo; Ping Li; Nian-yong Chen; Sha Zhao; Feng Wang; Li-qun Zou
Journal:  Cancer Med       Date:  2015-12-02       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.